<?xml version='1.0' encoding='utf-8'?>
<document id="20584745"><sentence text="Alprazolam as an in vivo probe for studying induction of CYP3A in cynomolgus monkeys."><entity charOffset="0-10" id="DDI-PubMed.20584745.s1.e0" text="Alprazolam" /></sentence><sentence text="Induction of the cytochrome P450 (P450) enzyme is a major concern in the drug discovery processes" /><sentence text=" To predict the clinical significance of enzyme induction, it is helpful to investigate pharmacokinetic alterations of a coadministered drug in a suitable animal model" /><sentence text=" In this study, we focus on the induction of CYP3A, which is involved in the metabolism of approximately 50% of marketed drugs and is inducible in both the liver and intestine" /><sentence text=" As a marker substrate for CYP3A activity, alprazolam (APZ) was selected and characterized using recombinant CYP3A enzymes expressed in Escherichia coli"><entity charOffset="43-53" id="DDI-PubMed.20584745.s5.e0" text="alprazolam" /><entity charOffset="55-58" id="DDI-PubMed.20584745.s5.e1" text="APZ" /><pair ddi="false" e1="DDI-PubMed.20584745.s5.e0" e2="DDI-PubMed.20584745.s5.e0" /><pair ddi="false" e1="DDI-PubMed.20584745.s5.e0" e2="DDI-PubMed.20584745.s5.e1" /></sentence><sentence text=" Both human CYP3A4 and its cynomolgus P450 ortholog predominantly catalyzed APZ 4-hydroxylation with sigmoidal kinetics"><entity charOffset="76-78" id="DDI-PubMed.20584745.s6.e0" text="APZ" /></sentence><sentence text=" When administered intravenously and orally to cynomolgus monkeys, APZ had moderate clearance; its first-pass extraction ratio after oral dosing was estimated to be 0"><entity charOffset="67-69" id="DDI-PubMed.20584745.s7.e0" text="APZ" /></sentence><sentence text="09 in the liver and 0" /><sentence text="45 in the intestine" /><sentence text=" Pretreatment with multiple doses of rifampicin (20 mg/kg p"><entity charOffset="37-47" id="DDI-PubMed.20584745.s10.e0" text="rifampicin" /></sentence><sentence text="o" /><sentence text=" for 5 days), a known CYP3A inducer, significantly decreased plasma concentrations of APZ after intravenous and oral administrations (0"><entity charOffset="86-95" id="DDI-PubMed.20584745.s12.e0" text="APZ" /></sentence><sentence text="5 mg/kg), and first-pass extraction ratios were increased to 0" /><sentence text="39 in the liver and 0" /><sentence text="63 in the intestine" /><sentence text=" The results were comparable to those obtained in clinical drug-drug interaction (DDI) reports related to CYP3A induction, although the rate of recovery of CYP3A activity seemed to be slower than rates estimated in clinical studies" /><sentence text=" In conclusion, pharmacokinetic studies using APZ as a probe in monkeys may provide useful information regarding the prediction of clinical DDIs due to CYP3A induction"><entity charOffset="46-48" id="DDI-PubMed.20584745.s17.e0" text="APZ" /></sentence><sentence text="" /></document>